Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 Combined With Nimotuzumab in Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
NCT06773130Phase 2Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic ductal adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Started Feb 2025; status: active, not recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06773130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773130.